glp-1 dual agonist Machine learning designs new GCGR/GLP-1R agonists with enhanced biological potency The current significance and prospects
Description
10.2337/db11-1506 [DOI] [PMC free article] [PubMed] [Google Scholar] 92.Baturcam E, Abubaker J, Tiss A, Abu-Farha M, Khadir A, Al-Ghimlas F, et al
Urgent need of treatment for AD and PD Despite considerable advances, existing AD and PD treatments primarily address the symptoms rather than the cause
*Correspondence: Yaqiu Jiang, [email protected] These authors have contributed equally to this work Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Other factors, such as participants health conditions, weight loss and metabolic improvements, may have influenced the results, researchers noted
The ability of peripherally circulating GLP-1 and GLP-1RAs to breach the blood-brain barrier remains uncertain
